RxDoctor Payments DataLook up a doctor →

Andrea Mabry, MD

Dermatology · Little Rock, ARNPI 1366709255

Payments from drug & device makers

$38,800in general payments, 2019–2025

Across 691 payments — averaging $56.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$14K
  • Sanofi US Services Inc.$14K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Novartis$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • plus $5K from 30 others

What the payments were for

  • Food & beverage$11,65696%
  • Education$5204%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,800 in reported general payments places this provider in the 90th percentile of 75 dermatology providers in Arkansas.

See all dermatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$445,266
Medicare patients
1,028
Services billed
6,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$170,266
Dupixent SyringeDupilumab26$105,179
OtezlaApremilast13$65,725
Tacrolimus53$5,617
Fluorouracil68$4,878
Clobetasol Propionate99$4,021
Ketoconazole206$3,845
Metronidazole46$2,721
Acitretin13$2,716
Fluocinonide78$2,708
Tretinoin16$2,468
ValacyclovirValacyclovir Hcl46$1,843
Triamcinolone Acetonide185$1,631
Doxycycline Hyclate102$1,377
Dutasteride74$1,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$99$65,72513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 75 dermatology providers in Arkansas.

Other dermatology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →